UCB0022

DRUG3 trials

Sponsors

UCB Biopharma SRL

Conditions

Healthy Study ParticipantsHealthy VolunteersParkinson DiseaseParkinson's Disease

Phase 1

A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease

CompletedNCT04867642

UCB Biopharma SRLHealthy Study Participants, Parkinson's Disease

Start: 2021-04-29End: 2023-02-27Updated: 2025-11-18

A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy Participants

CompletedNCT07220551

UCB Biopharma SRLHealthy Volunteers

Start: 2025-10-23End: 2025-12-16Updated: 2026-01-06

Phase 2

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease

CompletedNCT06055985

UCB Biopharma SRLParkinson Disease

Start: 2023-11-17End: 2025-04-11Updated: 2026-04-06